Advertisement

Retrograde Fas Ligand Signaling

  • Andreas Linkermann
  • Jing Qian
  • Ottmar Janssen
Chapter
  • 252 Downloads
Part of the Medical Intelligence Unit book series (MIUN)

Abstract

As highlighted in the previous chapters, the interaction of Fas with Fas Ligand (FasL) affects many different aspects related to activation and apoptosis of Fas-expressing immune and tumor cells. Over the past five years we have learned, however, that FasL also acts as a costimulatory or accessory molecule for T cell activation. In the following chapter, we summarize what is known about FasL as a modulator of thymocyte development and selection or a regulator of mature T cell activation and effector function. Since to date almost no data are available on how a putative T cell receptor (TCR) /CD3-FasL crosstalk biochemically might work, we discuss ideas and hypotheses about the orchestration of retrograde signaling events also in the context of what is known from other members of the TNF family.

Keywords

Casein Kinase Accessory Molecule Tumor Necrosis Factor Superfamily Tumor Necrosis Factor Family Member Tumor Necrosis Factor Superfamily Member 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Suzuki I, Fink PJ. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J Exp Med 1998; 187(1):123–128.PubMedCrossRefGoogle Scholar
  2. 2.
    Desbarats J, Duke RC, Newell MK. Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. Nat Med 1998; 4(12):1377–1382.PubMedCrossRefGoogle Scholar
  3. 3.
    Suzuki I, Fink PJ. The dual functions of fas ligand in the regulation of peripheral CD8+ and CD4+ T cells. Proc Natl Acad Sci USA 2000; 97(4):1707–1712.PubMedCrossRefGoogle Scholar
  4. 4.
    Suzuki I, Martin S, Boursalian TE et al. Fas ligand costimulates the in vivo proliferation of CD8+ T cells. J Immunol 2000; 165(10):5537–5543.PubMedGoogle Scholar
  5. 5.
    Brunner T, Yoo NJ, Griffith TS et al. Regulation of CD 95 ligand expression: A key element in immune regulation? Behring Inst Mitt 1996; 97:161–174.PubMedGoogle Scholar
  6. 6.
    French LE, Hahne M, Viard I et al. Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996; 133(2):335–343.PubMedCrossRefGoogle Scholar
  7. 7.
    Adachi M, Suematsu S, Suda T et al. Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc Natl Acad Sci USA 1996; 93(5):2131–2136.PubMedCrossRefGoogle Scholar
  8. 8.
    Sidman CL, Marshall JD, Von Boehmer H. Transgenic T cell receptor interactions in the lymphoproliferative and autoimmune syndromes of lpr and gld mutant mice. Eur J Immunol 1992; 22(2):499–504.PubMedCrossRefGoogle Scholar
  9. 9.
    Singer GG, Abbas AK. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994; 1(5):365–371.PubMedCrossRefGoogle Scholar
  10. 10.
    Kishimoto H, Surh CD, Sprent J. A role for Fas in negative selection of thymocytes in vivo. J Exp Med 1998; 187(9):1427–1438.PubMedCrossRefGoogle Scholar
  11. 11.
    Sprent J, Kishimoto H. The thymus and central tolerance. Philos Trans R Soc Lond B Biol Sci 2001; 356(1409):609–616.PubMedCrossRefGoogle Scholar
  12. 12.
    Singer A. New perspectives on a developmental dilemma: The kinetic signaling model and the importance of signal duration for the CD4/CD8 lineage decision. Curr Opin Immunol 2002; 14(2):207–215.PubMedCrossRefGoogle Scholar
  13. 13.
    Boursalian TE, Fink PJ. Mutation in fas ligand impairs maturation of thymocytes bearing moderate affinity T cell receptors. J Exp Med 2003; 198(2):349–360.PubMedCrossRefGoogle Scholar
  14. 14.
    Janssen O, Qian J, Linkermann A et al. CD 95 ligand-death factor and costimulatory molecule? Cell Death Differ 2003; 10(11):1215–1225.PubMedCrossRefGoogle Scholar
  15. 15.
    Hane M, Lowin B, Peitsch M et al. Interaction of peptides derived from the Fas ligand with the Fyn-SH3 domain. FEBS Lett 1995; 373(3):265–268.PubMedCrossRefGoogle Scholar
  16. 16.
    Wenzel J, Sanzenbacher R, Ghadimi M et al. Multiple interactions of the cytosolic polyproline region of the CD95 ligand: Hints for the reverse signal transduction capacity of a death factor. FEBS Lett 2001; 509(2):255–262.PubMedCrossRefGoogle Scholar
  17. 17.
    Ghadimi MP, Sanzenbacher R, Thiede B et al. Identification of interaction partners of the cytosolic polyproline region of CD95 ligand (CD178). FEBS Lett 2002; 519(1–3):50–58.PubMedCrossRefGoogle Scholar
  18. 18.
    Lussier G, Larose L. A casein kinase I activity is constitutively associated with Nck. J Biol Chem 1997; 272(5):2688–2694.PubMedCrossRefGoogle Scholar
  19. 19.
    Linkermann A, Qian J, Kabelitz D et al. The Fas Ligand as a death factor and signal transducer? Signal Transduction 2003; 3(1–2):33–46.CrossRefGoogle Scholar
  20. 20.
    Linkermann A, Qian J, Janssen O. Slowly getting a clue on CD95 ligand biology. Biochem Pharmacol 2003; 66(8):1417–1426.PubMedCrossRefGoogle Scholar
  21. 21.
    Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001; 104(4):487–501.PubMedCrossRefGoogle Scholar
  22. 22.
    Lens SM, Drillenburg P, den Drijver BF et al. Aberrant expression and reverse signalling of CD70 on malignant B cells. Br J Haematol 1999; 106(2):491–503.PubMedCrossRefGoogle Scholar
  23. 23.
    Cerutti A, Schaffer A, Goodwin RG et al. Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells. J Immunol 2000; 165(2):786–794.PubMedGoogle Scholar
  24. 24.
    Wiley SR, Goodwin RG, Smith CA. Reverse signaling via CD30 ligand. J Immunol 1996; 157(8):3635–3639.PubMedGoogle Scholar
  25. 25.
    van Essen D, Kikutani H, Gray D. CD40 ligand-transduced costimulation of T cells in the development of helper function. Nature 1995; 378(6557):620–623.PubMedCrossRefGoogle Scholar
  26. 26.
    Cayabyab M, Phillips JH, Lanier LL. CD40 preferentially costimulates activation of CD4+ T lymphocytes. J Immunol 1994; 152(4):1523–1531.PubMedGoogle Scholar
  27. 27.
    Miyashita T, McIlraith MJ, Grammer AC et al. Bidirectional regulation of human B cell responses by CD40-CD40 ligand interactions. J Immunol 1997; 158(10):4620–4633.PubMedGoogle Scholar
  28. 28.
    Blair PJ, Riley JL, Harlan DM et al. CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med 2000; 191(4):651–660.PubMedCrossRefGoogle Scholar
  29. 29.
    Langstein J, Michel J, Fritsche J et al. CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling. J Immunol 1998; 160(5):2488–2494.PubMedGoogle Scholar
  30. 30.
    Langstein J, Michel J, Schwarz H. CD137 induces proliferation and endomitosis in monocytes. Blood 1999; 94(9):3161–3168.PubMedGoogle Scholar
  31. 31.
    Stuber E, Neurath M, Calderhead D et al. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 1995; 2(5):507–521.PubMedCrossRefGoogle Scholar
  32. 32.
    Chen NJ, Huang MW, Hsieh SL. Enhanced secretion of IFN-gamma by activated Th1 cells occurs via reverse signaling through TNF-related activation-induced cytokine. J Immunol 2001; 166(1):270–276.PubMedGoogle Scholar
  33. 33.
    Scheu S, Alferink J, Potzel T et al. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J Exp Med 2002; 195(12):1613–1624.PubMedCrossRefGoogle Scholar
  34. 34.
    Shaikh RB, Santee S, Granger SW et al. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J Immunol 2001; 167(11):6330–6337.PubMedGoogle Scholar
  35. 35.
    Morel Y, Truneh A, Sweet RW et al. The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity. J Immunol 2001; 167(5):2479–2486.PubMedGoogle Scholar
  36. 36.
    Eissner G, Kirchner S, Lindner H et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol 2000; 164(12):6193–6198.PubMedGoogle Scholar
  37. 37.
    Chou AH, Tsai HF, Lin LL et al. Enhanced proliferation and increased IFN-gamma production in T cells by signal transduced through TNF-related apoptosis-inducing ligand. J Immunol 2001; 167(3):1347–1352.PubMedGoogle Scholar
  38. 38.
    Watts AD, Hunt NH, Wanigasekara Y et al. A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in ‘reverse signaling’. EMBO J 1999; 18(8):2119–2126.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2006

Authors and Affiliations

  • Andreas Linkermann
    • 1
  • Jing Qian
    • 1
  • Ottmar Janssen
    • 1
  1. 1.Institute of ImmunologyUniversity of KielKielGermany

Personalised recommendations